You are viewing the site in preview mode
Skip to main content
| | |
Univariate analysis
|
Multivariate analysis
|
|---|
|
OR (95% CI)
|
p-value
|
OR (95% CI)
|
p-value
|
|---|
|
BMI (kg/m2)
|
≥ 25
|
0.717 (0.406–1.268)
|
0.253
| | |
| |
< 25
|
1
| | | |
|
Age
|
≥ 30
|
0.544 (0.286–1.032)
|
0.063
|
–
|
–
|
| |
< 30
|
1
| | | |
|
Pathology
|
EAH
|
2.120 (1.186–3.789)
|
0.011
|
3.870 (1.175–12.742)
|
0.026
|
| |
EC
|
1
| |
1
| |
|
T2DM
|
Yes
|
0.816 (0.427–1.957)
|
0.914
| | |
| |
No
|
1
| | | |
|
PCOS
|
Yes
|
0.916 (0.476–1.764)
|
0.793
| | |
| |
No
|
1
| | | |
|
Hypothyroidism
|
Yes
|
1.842 (0.868–3.908)
|
0.111
| | |
| |
No
|
1
| | | |
|
Metformin
|
Yes
|
0.626 (0.324–1.210)
|
0.164
| | |
| |
No
|
1
| | | |
|
HOMA-IR
|
≥ 2.5
|
0.440 (0.210–0.921)
|
0.029
|
0.206 (0.056–0.755)
|
0.017
|
| |
< 2.5
|
1
| |
1
| |
|
T0-ER
| |
1.461 (0.676–3.158)
|
0.335
| | |
|
T0-PR
| |
1.198 (0.651–2.205)
|
0.561
| | |
|
T0-PRB
| |
2.560 (0.676–9.695)
|
0.167
| | |
|
T1 vs. T0-ER*
|
≥ 0
|
1.397 (0.599–3.256)
|
0.439
| | |
| |
< 0
|
1
| | | |
|
T1 vs. T0-PR*
|
≥ 60%
|
1.223 (0.504–2.971)
|
0.656
| | |
| |
< 60%
|
1
| | | |
|
T1 vs. T0-PRB*
|
≥ 30%
|
2.995 (1.201–7.469)
|
0.019
|
5.788 (1.531–21.889)
|
0.010
|
| |
< 30%
|
1
| |
1
| |
|
T0-Ki67
| |
1.002 (0.986–1.018)
|
0.826
| | |
- Bold part represents p-value less than or near 0.05
- *Defined as the range of reduction at the second assessment compared to the baseline level. OR: odds ratio; CI, confidence interval; EC, endometrial cancer; EAH, endometrial atypical hyperplasia; BMI, body mass index; T2DM, type 2 diabetes mellitus; PCOS, polycystic ovary syndrome
